论文信息 - Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19 - 字舞流文

Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19

D. Skovronsky | M. Frieman | N. Kallewaard | P. Chen | L. Wietecha | M. Azizad | M. Hufford | E. Chigutsa | A. Nirula | R. Gottlieb | D. Patel | L. Baracco | J. Potts | B. Jones | J. Morris | A. Igbinadolor | M. Williams | B. Feldman | L. Macpherson | S. Demmon | M. Dougan | P. N. Kumar | M. Williams